This conference will be the ultimate partnering event on the east coast – with opportunities for one-on-one partnering with the biggest names in the industry.
Access one-on-one partnering with hundreds of the biggest names in the industry.
Hear from experts from the life sciences community about the hottest topics in the industry.
Hear from top life sciences and investment organizations on what they are looking for to fill their portfolio.
Organizations will showcase their company’s services and network with other attendees.
Attendees from academic research institutions and spin-outs will present their cutting-edge science to a panel of reviewers.
Organizations will present their pitch deck for feedback and partnership opportunities.
Olympic Gold Medalist
Cancer Survivor & Activist
The most recognized male figure skating star in the world, Scott Hamilton has won 70 titles, awards and honors including an Emmy Award nomination, induction into the United States Olympic Hall of Fame and a privileged member of the World Figure Skating Hall of Fame.
After losing his mother to cancer, then becoming a survivor himself, Scott turned activist, launching the Scott Hamilton CARES Foundation (Cancer Alliance for Research, Education and Survivorship). He founded several education and survivorship programs including Chemocare.com and the fourth Angel Mentoring Program.
Professor, Medicine and Pediatrics
Director, Gene Therapy Program
James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. His research career spanning over 40 years has focused on rare diseases and ways to treat them by gene therapy.
The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.
Chairman & CEO
Krish Krishnan is the Chairman and CEO of Krystal Biotech, a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. In May 2023, the FDA approved VYJUVEK for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).
Throughout his career, Krish was specifically involved in two successful IPOs, the approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals to Shire Pharmaceuticals.
Tara Muzsi, Vice President, Immunology Sales & Marketing, Gastroenterology, Janssen
John Witkowski, President, DSM Biomedical
Mike Bowman, President & CEO, Valley Forge Tourism & Convention Board